Abstract:Background: Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication of copy number change in advanced prostate cancer, which defines a wide spectrum of disease from high-risk localised to metastatic, is unknown. Methods: We performed copy number profiling on 688 tumour regions from 300 patients, who presented with advanced prostate cancer prior to the start of long-term androgen deprivation therapy (ADT), in the control arm of the prospective randomised STAMPEDE trial. Patients were categorised into metastatic states as follows; high-risk non-metastatic with or without local lymph node involvement, or metastatic low/high volume. We followed up patients for a median of 7 years. Univariable and multivariable Cox survival models were fitted to estimate the association between the burden of copy number alteration as a continuous variable and the hazard of death or disease progression. Results: The burden of copy number alterations positively associated with radiologically evident distant metastases at diagnosis (P=0.00006) and showed a non-linear relationship with clinical outcome on univariable and multivariable analysis, characterised by a sharp increase in the relative risk of progression (P=0.003) and death (P=0.045) for each unit increase, stabilising into more modest increases with higher copy number burdens. This association between copy number burden and outcome was similar in each metastatic state. Copy number loss occurred significantly more frequently than gain at the lowest copy number burden quartile (q=4.1 × 10-6). Loss of segments in chromosome 5q21-22 and gains at 8q21-24, respectively including CHD1 and cMYC occurred more frequently in cases with higher copy number alteration (for either region: Kolmogorov-Smirnov distance, 0.5; adjusted P<0.0001). Copy number alterations showed variability across tumour regions in the same prostate. This variance associated with increased risk of distant metastases (Kruskal-Wallis test P=0.037). Conclusions: Copy number alteration in advanced prostate cancer associates with increased risk of metastases at diagnosis. Accumulation of a limited number of copy number alterations associates with most of the increased risk of disease progression and death. The increased likelihood of involvement of specific segments in high copy number alteration burden cancers may suggest an order underlying the accumulation of copy number changes. Trial registration: ClinicalTrials.gov NCT00268476 , registered on December 22, 2005. EudraCT 2004-000193-31 , registered on October 4, 2004.

Copy number alteration burden predicts prostate cancer relapse

Exome sequencing identified six copy number variations as a prediction model for recurrence of primary prostate cancers with distinctive prognosis

Accumulation of copy number alterations and clinical progression across advanced prostate cancer

Systematic Modeling of Risk-Associated Copy Number Alterations in Cancer

High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue

Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes

The landscape of somatic copy-number alteration across human cancers

Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma

Tumor Copy Number Alteration Burden as a Predictor for Resistance to Immune Checkpoint Blockade across Different Cancer Types

Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer

Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-Metastatic prostate Cancer

The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma.

Prognostic Relevance of Copy Number Losses in Ovarian Cancer

Mutation frequency and copy number alterations determine prognosis and metastatic tropism in 60,000 clinical cancer samples

BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression

Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study

Burden of Copy Number Alterations Predicts Outcomes in Immune Checkpoint Blockade Treated Gastrointestinal Cancer Patients.

Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors

Signatures of copy number alterations in human cancer

Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer